Immunosuppression With Antithymocyte Globulin, Rituximab, Tacrolimus, Mycophenolate Mofetil and Sirolimus, Followed by Withdrawal of Immunosuppression, in Living-donor Renal Transplant Recipients
Phase of Trial: Phase 0
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Antithymocyte globulin (Primary) ; Rituximab (Primary) ; Mycophenolate mofetil; Sirolimus; Tacrolimus
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms RESTARRT
- 02 Oct 2017 Status changed from active, no longer recruiting to discontinued.
- 03 May 2017 Early results presented at the 2017 American Transplant Congress
- 04 Feb 2016 Planned End Date changed from 1 Oct 2018 to 1 Jun 2020 as reported by ClinicalTrials.gov record.